Azitra, Inc.(AZTR)Earnings, Financials & Key Ratios

AZTR•AMEX

$0.15

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryMicrobiome and Phage Therapeutics

AboutAzitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.Show more

Revenue$0-100.0%
EBITDA-$11M+99.9%
Net Income-$11M-22.2%
EPS (Diluted)-2.25-532.2%
ROE-0.58%+99.7%

AZTR Price & Volume

Azitra, Inc. (AZTR) stock price & volume — 10-year historical chart

Loading chart...

Extreme Financial Anomalies Obscure Clinical Development Path

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Clinical trial funding dependency

Key Thesis Takeaways

Azitra remains a pre-commercial biotechnology entity characterized by persistent operational losses and significant data integrity concerns that complicate fundamental valuation.
The company's reliance on external capital to fund R&D is evidenced by a cumulative retained earnings deficit of $72.4 billion as of 2026Q1.
Investors should exercise extreme caution given the lack of recurring revenue and the presence of erratic, multi-billion dollar financial reporting outliers that deviate from standard micro-cap profiles.

Verdict Logic

the company's financial statements contain material reporting distortions, such as the $2.5 billion cash outflow in 2026Q1, which prevents a reliable assessment of the firm's actual liquidity and operational runway.

AZTR Growth Metrics

Azitra, Inc. (AZTR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-100%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-29.78%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-376.82%

Return on Capital

10 Years-46359.42%

5 Years-46359.42%

3 Years-77186.29%

Last Year-0.55%

AZTR Recent Earnings

Azitra, Inc. (AZTR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 4/12 qtrs (57%)

Q2 2026Latest

May 12, 2026

Metric

Actual

Est

EPS

$0.25-2400.0%

$0.01

Rev

—

Q2 2026

Mar 2, 2026

Metric

Actual

Est

EPS

$1.15-210.8%

$0.37

Rev

—

Q4 2025

Nov 12, 2025

Metric

Actual

Est

EPS

$0.67+15.2%

$0.79

Rev

—

Q3 2025

Aug 11, 2025

Metric

Actual

Est

EPS

$1.20+14.3%

$1.40

Rev

—

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 12, 2026	$0.25vs $0.01-2400.0%	—
Q2 2026	Mar 2, 2026	$1.15vs $0.37-210.8%	—
Q4 2025	Nov 12, 2025	$0.67vs $0.79+15.2%	—
Q3 2025	Aug 11, 2025	$1.20vs $1.40+14.3%	—

Based on last 12 quarters of dataView full earnings history →

Latest AZTR News

Recent stock market news and headlines for Azitra, Inc. (AZTR)

PRNewsWire·Jun 17, 2026

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

BRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Francisco Salva, Chief Executive Officer of Azitra, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond.

PRNewsWire·Jun 16, 2026

Azitra, Inc. to Present at 2026 BIO International Convention

/PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision

Peers Comparison

Key metrics vs top competitors for Azitra, Inc. (AZTR)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
AZTRAzitra, Inc.Current	$0.15	$1.63M	-0.07	-100%	—	-0.58%	—
MIRMMirum Pharmaceuticals, Inc.	$128.31	$6.44B	-273.00	54.74%	-194.97%	-289.33%	—
SLDBSolid Biosciences Inc.	$11.15	$868.7M	-5.60	—	—	-74.45%	—
KRYSKrystal Biotech, Inc.	$368.60	$10.87B	53.89	33.94%	53.92%	19.25%	—
QNCXQuince Therapeutics, Inc.	$17.50	$4.87M	-0.05	—	—	—	—
SNDXSyndax Pharmaceuticals, Inc.	$23.24	$2.05B	-7.06	627.84%	-112.01%	-256.66%	—

Compare AZTR vs Peers

Azitra, Inc. (AZTR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MIRM

Most directly comparable listed peer for AZTR.

Scale Benchmark

vs TMO

Larger-name benchmark to compare AZTR against a more recognizable public peer.

Peer Set

Compare Top 5

vs MIRM, SLDB, KRYS, QNCX

AZTR SEC Filings & Documents

Azitra, Inc. (AZTR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 13, 2026·SEC

Material company update

Mar 23, 2026·SEC

Material company update

Mar 13, 2026·SEC

10-K Annual Reports

FY 2026

Feb 27, 2026·SEC

FY 2025

Feb 24, 2025·SEC

FY 2024

Mar 15, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 13, 2026·SEC

FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 11, 2025·SEC

Get notified when AZTR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

AZTR Frequently Asked Questions

Azitra, Inc. (AZTR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

How fast is Azitra, Inc. growing?

Azitra, Inc. (AZTR) saw revenue decline by 100.0% over the past year.

Is AZTR profitable?

Azitra, Inc. (AZTR) reported a net loss of $11.8M for fiscal year 2025.

Dividend & Returns

What is AZTR's return on equity?

Azitra, Inc. (AZTR) has a return on equity (ROE) of -0.6%. Negative ROE indicates the company is unprofitable.

What is Azitra, Inc.'s free cash flow?

Azitra, Inc. (AZTR) had negative free cash flow of $2.50B in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in AZTR back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 12, 2026

$0.25vs $0.01-2400.0%

—

Q2 2026

Mar 2, 2026

$1.15vs $0.37-210.8%

—

Q4 2025

Nov 12, 2025

$0.67vs $0.79+15.2%

—

Q3 2025

Aug 11, 2025

$1.20vs $1.40+14.3%

—

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

AZTRAzitra, Inc.Current

$0.15

$1.63M

-0.07

-100%

—

-0.58%

—

MIRMMirum Pharmaceuticals, Inc.

$128.31

$6.44B

-273.00

54.74%

-194.97%

-289.33%

—

SLDBSolid Biosciences Inc.

$11.15

$868.7M

-5.60

—

-74.45%

—

KRYSKrystal Biotech, Inc.

$368.60

$10.87B

53.89

33.94%

53.92%

19.25%

—

QNCXQuince Therapeutics, Inc.

$17.50

$4.87M

-0.05

—

SNDXSyndax Pharmaceuticals, Inc.

$23.24

$2.05B

-7.06

627.84%

-112.01%

-256.66%

—